Search | Clinical Trials Finder

Conditions: Ovarian Cancer, Breast Cancer, Colorectal Cancer
Interventions: Genetic Testing and Counseling, Screening Form; Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: BRCA1-Related Hereditary Breast and Ovarian Cancer Syndrome, BRCA2-Related Hereditary Breast and Ovarian Cancer Syndrome, Hereditary Neoplastic Syndrome, Lynch Syndrome
Interventions: Discussion, Internet-Based Intervention, Survey Administration, Telephone-Based Intervention; Other · Behavioral
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Cancer
Interventions: therapeutic allogeneic lymphocytes; Biological
Lead sponsor: University of Medicine and Dentistry of New Jersey; Other
Eligibility: Not listed
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2011
U.S. locations: 1
States / cities: New Brunswick, New Jersey

Conditions: Cancer
Interventions: cytomegalovirus pp65-specific cytotoxic T lymphocytes, polymerase chain reaction, diagnostic laboratory biomarker analysis, flow cytometry, immunologic technique; Biological · Genetic · Other
Lead sponsor: University of Louisville; Other
Eligibility: 2 Years to 120 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: BRCA-Mutated Ovarian Carcinoma, BRIP1 Gene Mutation, MSH2 A636P, MLH1 Gene Mutation, MSH6 Gene Mutation, PMS2 Gene Mutation, EPCAM, RAD51C Gene Mutation
Interventions: CASCADE genetic screening; Other
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 99 Years
Enrollment: 118 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Infection, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Neuroblastoma, Ovarian Cancer, Testicular Germ Cell Tumor
Interventions: moxifloxacin hydrochloride, Placebo; Drug
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 18 Years to 120 Years
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Cancer, Hereditary Breast/Ovarian Cancer - BRCA1, Hereditary Breast/Ovarian Cancer - BRCA2, Male Breast Cancer, Progesterone Receptor-negative Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer, Triple-negative Breast Cancer
Interventions: veliparib, cisplatin, vinorelbine tartrate, laboratory biomarker analysis, pharmacological study; Drug · Other
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2017
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Hereditary Breast and Ovarian Cancer
Interventions: Genetic Counseling and Testing YouTube Video; Behavioral
Lead sponsor: Georgetown University; Other
Eligibility: 21 Years and older · Female only
Enrollment: 88 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Alexandria, Virginia

Conditions: Breast Cancer, Hereditary Breast Cancer
Interventions: Telephone Genetic Counseling; Behavioral
Lead sponsor: Georgetown University; Other
Eligibility: 21 Years to 90 Years · Female only
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2021
U.S. locations: 4
States / cities: Washington D.C., District of Columbia • Hackensack, New Jersey • Alexandria, Virginia + 1 more

Conditions: Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Graft Versus Host Disease, Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Neuroblastoma, Ovarian Cancer, Testicular Germ Cell Tumor
Interventions: beclomethasone dipropionate; Drug
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 5 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2002
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: BRCA1/2-Associated Hereditary Breast and Ovarian Cancer Syndrome
Interventions: Best Practice, Biospecimen Collection, Counseling, Discussion, Genotyping, Molecular Risk Assessment, Questionnaire Administration; Other · Procedure
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 2
States / cities: Columbus, Ohio • Salt Lake City, Utah

Conditions: Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, BRCA-Associated Malignant Neoplasm, BRCA Hereditary Ovarian Carcinoma, Metastatic BRCA Hereditary Breast Carcinoma, Metastatic Breast Carcinoma, Metastatic Fallopian Tube Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Ovarian Carcinoma, Metastatic Pancreatic Carcinoma, Metastatic Primary Peritoneal Carcinoma, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8, Stage III Fallopian Tube Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage III Primary Peritoneal Cancer AJCC v8, Stage IV Fallopian Tube Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Stage IV Primary Peritoneal Cancer AJCC v8, Unresectable Breast Carcinoma, Unresectable Fallopian Tube Carcinoma, Unresectable Malignant Solid Neoplasm, Unresectable Ovarian Carcinoma, Unresectable Pancreatic Carcinoma, Unresectable Primary Peritoneal Carcinoma
Interventions: Dostarlimab, Niraparib, Biopsy, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging; Biological · Drug · Procedure
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Breast Cancer
Interventions: Video and Booklet, Factsheet; Behavioral
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older · Female only
Enrollment: 157 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Cancer
Interventions: infection prophylaxis and management; Procedure
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 12 Years to 60 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1995 – 2002
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Adult Solid Neoplasm, BRCA1 Mutation Carrier, BRCA2 Mutation Carrier, Hereditary Breast and Ovarian Cancer Syndrome
Interventions: Carboplatin, Laboratory Biomarker Analysis, Paclitaxel, Pharmacological Study, Veliparib; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 7
States / cities: Duarte, California • Los Angeles, California • Sacramento, California + 3 more

Conditions: Lymphoma
Interventions: Not listed
Lead sponsor: Mayo Clinic; Other
Eligibility: Not listed
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 1
States / cities: Scottsdale, Arizona

Conditions: Hereditary Breast/Ovarian Cancer (brca1, brca2), Lynch Syndrome, Genetic Variation, HBOC Syndrome, Hereditary Cancer Syndromes
Interventions: Patient Centered Clinical Decision Support (PC-CDS); Other
Lead sponsor: HealthPartners Institute; Other
Eligibility: 18 Years and older
Enrollment: 2,488 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Extensive Stage Small Cell Lung Cancer, Hereditary Paraganglioma, Male Breast Cancer, Malignant Paraganglioma, Metastatic Gastrointestinal Carcinoid Tumor, Metastatic Pheochromocytoma, Pancreatic Polypeptide Tumor, Recurrent Breast Cancer, Recurrent Cervical Cancer, Recurrent Endometrial Carcinoma, Recurrent Gastrointestinal Carcinoid Tumor, Recurrent Islet Cell Carcinoma, Recurrent Neuroendocrine Carcinoma of the Skin, Recurrent Non-small Cell Lung Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Ovarian Germ Cell Tumor, Recurrent Pheochromocytoma, Recurrent Prostate Cancer, Recurrent Renal Cell Cancer, Recurrent Small Cell Lung Cancer, Recurrent Uterine Sarcoma, Regional Gastrointestinal Carcinoid Tumor, Regional Pheochromocytoma, Stage III Cervical Cancer, Stage III Endometrial Carcinoma, Stage III Neuroendocrine Carcinoma of the Skin, Stage III Ovarian Epithelial Cancer, Stage III Ovarian Germ Cell Tumor, Stage III Prostate Cancer, Stage III Renal Cell Cancer, Stage III Uterine Sarcoma, Stage IIIA Breast Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Breast Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage IV Endometrial Carcinoma, Stage IV Neuroendocrine Carcinoma of the Skin, Stage IV Non-small Cell Lung Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Ovarian Germ Cell Tumor, Stage IV Prostate Cancer, Stage IV Renal Cell Cancer, Stage IV Uterine Sarcoma, Stage IVA Cervical Cancer, Stage IVB Cervical Cancer, Thyroid Gland Medullary Carcinoma
Interventions: temsirolimus, vinorelbine ditartrate; Drug
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Cancer
Interventions: entinostat; Drug
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2008
U.S. locations: 3
States / cities: Bethesda, Maryland

Conditions: Cervical Cancer, Endometrial Cancer, Fallopian Tube Cancer, Hereditary Breast/Ovarian Cancer (brca1, brca2), Ovarian Cancer, Sarcoma, Uterine Leiomyomata, Vaginal Cancer, Vulvar Cancer
Interventions: Ca-125, screening questionnaire administration, Surgery; Other · Procedure
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 80 Years · Female only
Enrollment: 6,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2000 – 2040
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Breast Cancer, Ovarian Cancer
Interventions: AZ2281 + Carboplatin; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 100 Years
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2019
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Breast Cancer, Colorectal Cancer, Ovarian Cancer, Prostate Cancer, Pancreatic Cancer, Endometrial Cancer, History of Cancer
Interventions: Publicly available genetic testing resources, Virtual genetics navigator, Motivational interviewing (MI); Other · Behavioral
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 831 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Hereditary Breast and Ovarian Cancer Syndrome, Osteoporosis, Ovarian Carcinoma
Interventions: Laboratory Biomarker Analysis, Zoledronic Acid; Other · Drug
Lead sponsor: Gynecologic Oncology Group; Network
Eligibility: Female only
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 95
States / cities: Scottsdale, Arizona • Tucson, Arizona • Burbank, California + 76 more

Conditions: Breast Cancer, Ovarian Cancer
Interventions: E39 peptide vaccine, E39 vaccine then J65 vaccine, J65 vaccine then E39 vaccine; Biological
Lead sponsor: COL George Peoples, MD, FACS; Federal
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Houston, Texas

Search by objective public record fields.

Identifying Underserved Individuals inTexas With Hereditary Cancer Risk Using Mobile Mammography Units and Telegenetics.

A Web-Based Program (Kindred) to Improve the Understanding of Genetic Cancer Risk and Cancer Genetic Testing in African American Families

Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor

Vaccine Therapy in Treating Patients Who Have Undergone a Donor Stem Cell Transplant and Have Cytomegalovirus Infection That Has Not Responded to Therapy

Cascade Testing in Families With Newly Diagnosed Hereditary Breast and Ovarian Cancer Syndrome

Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell Transplant

Veliparib, Cisplatin, and Vinorelbine Ditartrate in Treating Patients With Recurrent and/or Metastatic Breast Cancer

Enhancing At-risk Latina Women's Use of Genetic Counseling for Hereditary Breast and Ovarian Cancer

Testing a Culturally Adapted Telephone Genetic Counseling Intervention

Beclomethasone in Treating Patients With Graft-Versus-Host Disease of the Esophagus, Stomach, Small Intestine, or Colon

Clinical Impact of Enhanced Risk Assessments in Women With a BRCA1/2 Mutation, CARE Study

Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer

Genetic Counseling for Breast Cancer Survivors (GC for BC)

Immunotherapy in Treating Patients Who Are Undergoing Bone Marrow or Peripheral Stem Cell Transplantation

Veliparib, Carboplatin, and Paclitaxel in Treating Patients With Advanced Solid Cancer

Early Detection of Graft-Versus-Host Disease in Patients Undergoing a Donor Bone Marrow Transplant

Patient Centered Clinical Decision Support for Hereditary Cancer Syndromes

Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors

MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma

Specimen and Data Study for Ovarian Cancer Early Detection and Prevention

AZD2281 Plus Carboplatin to Treat Breast and Ovarian Cancer

Michigan Genetic Hereditary Testing (MiGHT)

Zoledronate or Observation in Maintaining Bone Mineral Density in Patients Who Are Undergoing Surgery to Remove Both Ovaries

Phase Ib Trial of Two Folate Binding Protein Peptide Vaccines (E39 and J65) in Breast and Ovarian Cancer Patients